STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
|
|
- Stuart Greene
- 7 years ago
- Views:
Transcription
1 Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol 1. BACKGROUND This Standard Operating Procedure (SOP) describes procedures for identifying and reporting serious breaches of Good Clinical Practice (GCP) or study protocol. The EU GCP Directive 2005/28/EC was transposed into UK law as the Medicines for Human Use (Clinical Trials) Amendment Regulations 2006, together with the Medicines for Human Use (Clinical Trials) Regulations Under the amendment it is now a requirement that serious breaches of GCP or the study protocol are reported to the Medicines and Healthcare products Regulatory Agency (MHRA) (if appropriate), Research Ethics Committee (REC) in addition to the sponsor and Basildon and Thurrock University Hospitals NHS Foundation Trust (BTUH) research and development (R&D) department. The amended regulations state: 29A. (1) The sponsor of a clinical trial shall notify the licensing authority in writing of any serious breach of (a) The conditions and principles of GCP in connection with that trial; or (b) The protocol relating to that trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach. (2) For the purposes of this regulation, a serious breach is a breach which is likely to effect to a significant degree (a) The safety or physical or mental integrity of the subjects of the trial; or (b) The scientific value of the trial It is the responsibility of the study sponsor or a person legally authorised by the sponsor to carry out the notification procedure within 7 days of becoming aware of the breach. Examples of serious breaches are show below and in Appendix 1; Failure to obtain informed consent (i.e. no documentation in source data or an Informed Consent Form) Enrolment of subjects that do not meet the inclusion/exclusion criteria Undertaking a study procedure not approved by the REC and/or the Medicines and Healthcare products Regulatory Authority (MHRA) (unless for immediate safety reasons) Page 1 of 5
2 Failure to report a serious adverse event (SAE), serious adverse reaction (SAR) or suspected unexpected SAR (SUSAR ) to the sponsor Investigational medicinal product (IMP) dispensing/dosing error Deviations from research study protocols and GCP occur commonly in research studies. The majority of these instances are technical deviations that do not result in harm to the research participant or significantly affect the scientific value of the reported results of the study. These cases should be documented e.g. in the case report form (CRF) for the study, in order for appropriate corrective and preventative actions to be taken. In addition, these deviations should be included and considered when the study report is produced (if BTUH sponsored), as they may have an impact on the analysis of the data. However, not every deviation from the protocol needs to be reported to the REC/MHRA as a serious breach. The reporting procedures for protocol violation/deviation are usually defined in the research study protocol. It is the responsibility of the to assess the impact of the breach on the scientific value of the study. Anyone who is unsure whether a breach has occurred can contact the R&D department to discuss the situation and clarify whether a breach is classed as serious. 2. PURPOSE The purpose of this SOP is to; outline procedures for identifying a potential serious breach of GCP or protocol violation describe the process for notification of serious breaches of GCP or the approved study protocol ensure appropriate assessments are carried out by relevant parties and fully documented outline the role of the R&D department in assessing the reported serious breaches and the escalation process 3. APPLICABLE TO This SOP applies to all staff involved in research studies sponsored or hosted by BTUH. For research studies sponsored by BTUH, notification of serious breaches should be directed to the study CI or delegated individual within 24 hours of being aware of the serious breach. For research studies hosted by BTUH, notification of serious breaches should be directed to the study sponsor within the specified timescales. The Associate Director of R&D should also be informed if a serious breach has occurred within BTUH whether BTUH sponsored or hosted. 4. PROCEDURE It is the responsibility of the CI and Principal Investigator(s) (PIs) to continually monitor the conduct of the research study; this may be delegated to a suitably qualified or experienced member of the research team or sub-contracted to an appropriately qualified party (e.g. coordinating centre). 4.1 BTUH ed Studies Procedure Identifying and Notification of a Serious Breach Page 2 of 5
3 If a possible protocol violation and/or GCP breach has been identified, the CI should carry out an assessment to confirm if the event affects the safety, physical or mental integrity of the research participant or the scientific value of the study. If yes, this should be treated as a possible serious breach and should be investigated further. However, if the event only relates to a protocol violation, then record the event as per protocol requirements. Any potential serious breaches of GCP identified either through monitoring, audit or by other means must be reported to the Associate Director of R&D within 24 hours of the breach being identified. For BTUH sponsored multicentre research studies, the process for identifying breaches should be provided to all participating sites at study set up. BTUH/sponsor should also ensure that adequate procedures are in place as part of the routine monitoring processes to identify potential GCP breaches. If a possible breach has been reported by a PI at a participating site or identified as part of the routine monitoring process, this SOP should be followed to conduct the necessary assessment and reporting required by the sponsor Assessment of a Serious Breach Upon notification of an initial breach report, R&D will discuss the issue with the CI or delegated individual to identify which section of GCP or the protocol has been breached and how the breach impacts the participants safety and/or the scientific integrity of the study. R&D will meet with the site study team to discuss the breach and compile evidence to support notification to the appropriate bodies. This will then be sent to the CI and related departments e.g. pharmacy, for approval. R&D will work with the study team to identify the extent of the breach and to initiate any urgent safety measures that may be required Initial Notification of Breach to external bodies CI/BTUH/sponsor will collate all available information and the PI and R&D will assist as required, the breach would then be reported to REC and MHRA (as appropriate) on the necessary forms, see Health Research Authority (HRA) and MHRA websites for most current forms Outcome The outcome of any serious breach along with corrective measures will be discussed with the PI and research team. Depending on the severity and frequency of the serious breach the site team may require additional training and monitoring and, as a last resort, the site may be suspended to further recruitment. 4.2 BTUH Hosted Studies Procedure Identifying and Notifying of a Serious Breach If a possible breach has been reported by a PI at a participating site or identified by the as part of the routine monitoring process, this SOP should be followed to conduct the necessary assessment and reporting required by the sponsor. Page 3 of 5
4 If BTUH R&D identifies the serious breach via our internal audit system the PI should notify the CI/sponsor within 24 hours of BTUH R&D becoming aware of the event Assessment and Outcome of a Serious Breach The PI and research team will provide the CI/sponsor with all necessary information to assist with the assessment of a serious breach in GCP. Any actions identified by the CI/sponsor should be implemented as soon as practical Other Reporting Requirements and Implementing Corrective and Preventative Action Any possible serious breach that occurs may also require reporting via BTUHs incident reporting system. The R&D Office shall make recommendations to the study team about where further reporting requirements apply. The R&D Office will work with the study team to devise a formal plan of corrective and preventative action to address the breach. Depending on the initial assessment of seriousness and impact, R&D may carry out a full audit of the study and general study management systems and procedures. 5. SUPPORTING DOCUMENTS Research Management and Governance Manual (CP/PO/00136) 6. REFERENCES SI 2004/1031: The Medicines for Human Use (Clinical Trials) Regulations 2004 SI 2006/1928: The Medicines for Human Use (Clinical Trials) Amendment Regulations APPENDICES Appendix 1: MHRA Serious Breach Examples 8. DOCUMENT HISTORY Revision Date Previous Revision Date Summary of Changes July 2014 New SOP Removing information regarding BTUH as sponsor requiring Competent Authority (MHRA) approval Changes Marked Whole document Page 4 of 5
5 APPENDIX 1: MHRA Serious Breach Example Notifier Breach Is it considered a Serious Breach? Dosing error. Ethics Committee & MHRA No. As no significant impact on the integrity of trial informed. Subjects withdrawn. The sponsor subjects or on scientific validity of the trial. stated that there were no serious consequences to subjects or data. Patient Information Leaflet and Informed Possibly not. If this was not a systematic or persistent Consent updated. At one trial site this was not problem and if no harm to trial subjects resulted from relayed to the patients until approximately 2-3 the delay. months after approval. More information on the potential consequences of the delay Yes, if there was a significant impact on the integrity should have been provided. of trial subjects (e.g. there was key safety information not relayed to subjects in a timely manner etc.). Visit date deviation. A common deviation in clinical trials. No. Minor protocol deviation, which does not meet the criteria for notification. Contractor Identified during an Inspection Investigator failed to report a single SAE as No, if it did not result in this or other trial subjects defined in the protocol (re-training provided). being put at risk, and if it was not a systematic or persistent problem. In some circumstances, failure to report a SUSAR could have a significant impact on trial subjects. Sufficient information and context should be provided for the impact to be assessed adequately. Investigator site failed to reduce or stop trial Yes medication, in response to certain laboratory parameters, as required by the protocol. This occurred with several patients over a one year period, despite identification by the monitor of the first two occasions. Patients were put at increased risk of thrombosis. Became aware of fraud at an investigator site Although, in this situation, not a legal requirement in the UK, which did not affect the overall under 29A, MHRA encourages voluntary reporting of scientific value of the s trial or the all fraud cases in the UK, because MHRA will need to integrity of trial subjects in the UK. However, establish the impact on the other trials in case subject the is aware that the investigator site integrity or the scientific value of those trials was was also involved in trials being sponsored by compromised. other organisations. IMP temperature excursions reported No, if the excursions had been managed appropriately (i.e. IMP moved to Alternative location/quarantined as necessary and it was identified by qualified personnel that there was no impact on stability of the product and therefore no impact on patient safety/data integrity). Yes, if this went unmanaged and subjects were dosed with the IMP were found to have become unstable and this resulted in harm or potential harm to subjects Page 5 of 5
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s Author: Lisa Austin, Research Manager Purpose and Objective: To identify and standardise
More informationStandard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL
Page 1 of 10 Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL SOP ID Number: Effective Date:01/08/2012 Version Number & Date of Authorisation: V02,
More informationSerious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd
Serious Breaches Ian Gravenor Senior Clinical Project Manager Novo Nordisk Ltd Serious Breaches of GCP or the Trial Protocol Agenda Why report? The legislation MHRA Guidance document Timelines Actions
More informationMarie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager
Standard Operating Procedures (SOP) for: Monitoring SOP 28 Version 7.0 Number: Number: Effective Date: 29 th November 2015 Review Date: 6 th January 2017 Author: Reviewer: Reviewer: Authorisation: Name
More informationDocument Title: Project Management of Papworth Sponsored Studies
Document Title: Project Management of Papworth Sponsored Studies Document Number: SOP009 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G
More informationArchiving of Research Documentation
Suspension, Termination & Completion Standard Operating Procedure VERSION / REVISION: 2.0 EFFECTIVE DATE: 28 05 12 REVIEW DATE: 28 05 14 AUTHOR(S): CONTROLLER: APPROVED BY: Clinical Trials Manager; Recruitment
More informationROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS
ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:
More informationPolicy Flowchart. Policy Title: Research Governance, Conduct and Management Policy. Reference and Version No: IG6 Version 5
Policy Title: Research Governance, Conduct and Management Policy Reference and Version No: IG6 Version 5 Author and Job Title: J Greenaway Research and Development Manager Executive Lead Medical Director
More informationTRIAL MASTER FILE- SPONSORED
gsop-06-04 - Management of TMF for ENHT/ WHHT Sponsored CTIMPs Page 1 of 16 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust TRIAL MASTER
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationINTERIM SITE MONITORING PROCEDURE
INTERIM SITE MONITORING PROCEDURE 1. PURPOSE The purpose of this SOP is to describe the interim monitoring procedures conducted at Institution, according to GCP and other applicable local regulations.
More informationDocument Title: Trust Approval and Research Governance
Document Title: Trust Approval and Research Governance Document Number: SOP034 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationgsop-32-02 - Vendor Assessment SOP page 1 of 10
gsop-32-02 - Vendor Assessment SOP page 1 of 10 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust VENDOR ASSESSMENT Research & Development
More informationUK Implementation of the EU Clinical Trial Directive 2001/20/EC:
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
More informationR&D Administration Manager. Research and Development. Research and Development
Document Title: Document Number: Patient Recruitment SOP031 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D Administration Manager,
More informationCONTROLLED DOCUMENT- DO NOT COPY STANDARD OPERATING PROCEDURE. STH Investigator
Research Department STANDARD OPERATING PROCEDURE STH Investigator Archiving of Essential Documentation Generated During Clinical Research SOP Number A127 Version Number V1.3 Effective Date Author Zoe Whiteley
More informationDorset Research Consortium. Research Governance: A handbook for Researchers in Dorset
Dorset Research Consortium Research Governance: A handbook for Researchers in Dorset DRC Version 1 dated 25 th July 2012 Research Governance: The Basics... 4 What is Research Governance?... 4 The Research
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Undertaking Risk Assessment of a Research and Development Project SOP Number: 33 Version Number: 1.0 Supercedes: N/A Effective
More informationDESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004
DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Page 1 of 17 TABLE OF CONTENTS INTRODUCTION 4 EXECUTIVE SUMMARY 4 PUBLIC HEALTH BENEFITS 5 Good clinical practice 5 Good manufacturing
More informationJoint Research Office
Office Location: 1 st Floor Maple House 149 Tottenham Court Road London W1T 7DN Joint Research Office Postal Address: UCL, Gower Street London WC1E 6BT Email: hameedah.bogle-dawoud@nhs.net Tel No. 020
More informationThe EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
More informationEssentials of RESEARCH GOVERNANCE
Promoting Good Practice in Research Essentials of RESEARCH GOVERNANCE Information for Researchers, Students and Support Staff involved in Health & Social Care Research 2005 Reproduced with the permission
More informationClinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity
Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Michelle Quaye Regulatory Manager, Advanced Therapy Trials University College London Overview The Principles of Good
More informationSTANDARD OPERATING PROCEDURE. Risk Assessment of STH sponsored CTIMPs
Research Department STANDARD OPERATING PROCEDURE of STH sponsored CTIMPs SOP History None SOP Number C118 Created STH Research Department (EW) Reviewed STH Research Department (EW) Superseded Version 1.0,
More informationWhat is necessary to provide good clinical data for a clinical trial?
What is necessary to provide good clinical data for a clinical trial? Alain Barrois, Assistant Clinical Trials Operations Manager #EBMT2015 www.ebmt.org Is this a (typical) clinical trial? 2 Agenda Introduction
More informationSummary of the role and operation of NHS Research Management Offices in England
Summary of the role and operation of NHS Research Management Offices in England The purpose of this document is to clearly explain, at the operational level, the activities undertaken by NHS R&D Offices
More informationRESEARCH AND DEVELOPMENT GAINING NHS RESEARCH PERMISSION FROM CARDIFF AND VALE UHB - GUIDANCE FOR RESEARCHERS. Research Governance Group
RESEARCH AND DEVELOPMENT GAINING NHS RESEARCH PERMISSION FROM CARDIFF AND VALE UHB - GUIDANCE FOR RESEARCHERS Reference No: UHB 074 Version No: 5 Previous Trust / LHB Ref No: N/A Documents to read alongside
More informationResearch Study Close-down and Archiving Procedures
Title: Outcome Statement: Research Study Close-down and Archiving Procedures To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More informationGood Clinical Practice (GCP)
Good Clinical Practice (GCP) Joanne Thompson Clinical Trials Monitor and Trainer, UHL Dec 2011 1 1 What is GCP? An international ethical and scientific quality standard for designing, conducting, recording
More informationQuality Monitoring Checklist
Quality Monitoring Checklist Instructions: For each task below, the Quality Monitor indicates in the appropriate column if the Monitor accomplished the task by using the following codes Yes No N/A = Monitor
More informationRESEARCH GOVERNANCE POLICY
RESEARCH GOVERNANCE POLICY Policy Title Version: Approved by: Date of approval: 29 June 2015 Policy supersedes: Lead Board Director: Policy Lead (and author if different): Name of responsible committee/group:
More informationEssential Documentation and the Creation and Maintenance of Trial Master Files
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationLegal and governance framework
Annex A Legal and governance framework This annex is a brief guide to the legal and governance framework relevant to research in the UK. It is not intended to be a comprehensive statement of the law or
More informationThe Study Site Master File and Essential Documents
The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010
More informationSOP Number: SOP-QA-34 Version No: 1. Version Description of Changes Date Effective. Change of number for Q-Pulse (Replaces UoA-NHSG-SOP-051 V1)
Standard Operating Procedure: SOP Number: SOP-QA-34 Version No: 1 Author: Date: 1-9-15 (Carole Edwards, Lead Research Nurse, NHS Grampian) Approved by: Date: 1-9-15 (Professor Julie Brittenden, R&D Director,
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark Question 1: What laws or regulations apply to an application for conducting a clinical
More informationManaging Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey
Managing Risk in Clinical Research Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Aim of the session To explore the risks associated with clinical research and understand how
More informationStandard Operating Procedure for the Recording, Management and Reporting of Adverse Events by Investigators
ASR\INV_S05_SOP for AE_SAE_Reporting by Inv_V06.doc Page 1 of 19 Standard Operating Procedure for the Recording, Management and Reporting of Adverse Events by Investigators SOP Number: Effective Date:
More informationTrust/Host Site Approval. Presented by: Anika Kadchha Research Governance Officer
Trust/Host Site Approval Presented by: Anika Kadchha Research Governance Officer Joint Research & Enterprise Office Training 19 th January Outline What is Research NHS Ethics (if required) Host Site Approval
More informationDocument Title: Supply of Clinical Trials Investigational Material: Dispensing, Returns and Accountability
Document Title: Supply of Clinical Trials Investigational Material: Document Number: SOP072 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationReflection paper for laboratories that perform the analysis or evaluation of clinical trial samples
28 February 2012 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group Reflection paper for laboratories that perform the analysis or evaluation of clinical trial Draft agreed by GCP Inspectors Working
More informationRECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. Management of Essential Documents and Trial Folders
STANDARD OPERATING PROCEDURE FOR RESEARCH Management of Essential Documents and Trial Folders Author Linda Ward Author s Job Title QA Coordinator Division Department Version number 2 Ref SOP/CLN/001/2
More informationJRO RMG RSS SOP 12. Standard Operating Procedure (SOP) for Study Closedown and Archiving Royal Free site specific SOP
Office Location: 1 st Floor Maple House 149 Tottenham Court Road London W1T 7DN Joint Research Office Tel No. 0845 1555 000 Web-sites: www.uclh.nhs.uk; www.ucl.ac.uk/jro Postal Address: UCL, Gower Street
More informationArchiving of Clinical Trial Data and Essential Documentation JCTO/CT/SOP 4.0. Joint Clinical Trials Office. Stuart Hatcher, JCTO Archivist
Archiving of Clinical Trial Data and Essential Documentation Policy Details Document Type Standard Operating Procedure Document name Change History Date Version Number JCTO/CT/SOP 4.0 Version Final v 2.0-09/11/2010
More informationThis SOP may also be used by staff from other NHS areas, or organisations, with prior agreement.
Standard Operating Procedure: SOP Number: SOP-QA-32 Version No: 1 Author: Date: (Gary Cooper, Named Sponsor Archivist, NHS Grampian and University of Aberdeen) 1-9-15 Approved by: Date: 1-9-15 (Professor
More informationStandard Operating Procedure for Archiving Essential Documentation relating to Clinical Trials of Investigational Medicinal Products (CTIMPs)
archiving\spon_s21_sop_for_archiving V02.doc Page 1 of 13 Standard Operating Procedure for Archiving Essential Documentation relating to Clinical Trials of Investigational Medicinal Products (CTIMPs) SOP
More informationSOP Number: SOP-QA-20 Version No: 1. Author: Date: 1-9-15 (Patricia Burns, Research Governance Manager, University of Aberdeen)
Standard Operating Procedure: SOP Number: SOP-QA-20 Version No: 1 Author: Date: 1-9-15 (Patricia Burns, Research Governance Manager, University of Aberdeen) Approved by: Date: 1-9-15 (Professor Julie Brittenden,
More informationIntroduction 2. 1. The Role of Pharmacy Within a NHS Trust 3. 2. Pharmacy Staff 4. 3. Pharmacy Facilities 5. 4. Pharmacy and Resources 6
Index Index Section Page Introduction 2 1. The Role of Pharmacy Within a NHS Trust 3 2. Pharmacy Staff 4 3. Pharmacy Facilities 5 4. Pharmacy and Resources 6 5. Prescription Charges 7 6. Communication
More informationA Guide to Pharmacy Documentation For Clinical Trials
A Guide to Pharmacy Documentation For Clinical Trials Roy Sinclair Clinical Trials Pharmacist St. George s Hospital (to Sep 2007) Lecturer Kingston University January 2008 A Guide to Pharmacy Documentation
More informationManaging & Validating Research Data
Research Management Standard Operating Procedure ISOP-H02 VERSION / REVISION: 2.0 EFFECTIVE DATE: 01 03 12 REVIEW DATE: 01 03 14 AUTHOR(S): CONTROLLER(S): APPROVED BY: Information Officer; NBT Clinical
More informationIndustry Experience in Clinical Trials Management. Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels
Industry Experience in Clinical Trials Management Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels Stakeholders in clinical research Critical activities to ensure patient
More informationTrial Delivery SOP 05 Trial Archiving
Gloucestershire Research and Development Consortium Standard Operating Procedure R&D SOP TD 05Trial Archiving Trial Delivery SOP 05 Trial Archiving IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO
More informationPERFORMANCE IN INITIATING CLINICAL RESEARCH (PI) CLINICAL TRIALS DATA RECORD ADJUSTMENT PROCESS
PERFORMANCE IN INITIATING CLINICAL RESEARCH (PI) CLINICAL TRIALS DATA RECORD ADJUSTMENT PROCESS Version Control Amended small error in Acronyms table (page 2) 1 Acronyms CTP FPR MHRA REC SOP TMB VRA Clinical
More informationICRIN Seminar on EU Regulation of Clinical Trials
ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation
More information12.0 Investigator Responsibilities
v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,
More informationTEMPLATE DATA MANAGEMENT PLAN
TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationCLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]
CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE] CONTRACT RESEARCH ORGANIZATION SPONSOR [NAME] [ADDRESS] 1 TABLE OF CONTENTS 1. Purpose 3 2. References 3 3. Study Roles and Responsibilities
More informationResearch & Development Directorate
Research & Development Directorate Type of Document Standard Operating Procedure Name SOP10: Routine Audit Version 3.0 Author Miss Jennifer Boyle (Research Governance Co-ordinator) Version Superseded 2.4
More informationThe role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations
The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations Maria Luisa Paoloni OPBG Clinical & Research Services Monitoring and Responsible of monitoring:
More informationDocument Title: Research Database Application (ReDA)
Document Title: Research Database Application (ReDA) Document Number: SOP035 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationCONTROLLED DOCUMENT. Uncontrolled Copy. RDS014 Research Related Archiving. University Hospitals Birmingham NHS Foundation Trust
University Hospitals Birmingham NHS Foundation Trust CONTROLLED DOCUMENT RDS014 Research Related Archiving CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 1 Controlled Document
More informationWorking Instruction Template. Instructions for Archiving of Essential Trial Documents at Datatron Off Site Facility
Working Instruction Template WI number: WI full title: WI-JRO-001 Instructions for Archiving of Essential Trial Documents at Datatron Off Site Facility WI effective: 28 th October 2013 Review date: 28
More informationClinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Russia
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Russia Question 1: What laws or regulations apply to an application for conducting a clinical
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationStudy Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
More informationGuidance for CTUs on Assessing the Suitability of Laboratories Processing Research Samples
Guidance for CTUs on Assessing the Suitability of Laboratories Processing Research Samples UKCRC Registered CTUs Network Guidance for CTUs on Assessing the Suitability of Laboratories Processing Research
More informationGOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE
ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's
More informationCHILDREN AND ADULTS SERVICE RESEARCH APPROVAL GROUP
DURHAM COUNTY COUNCIL CHILDREN AND ADULTS SERVICE RESEARCH APPROVAL GROUP INFORMATION PACK Children and Adults Service Version 4 October 2015 Children and Adults Service Research Approval Group Page 1
More informationand Regulatory Aspects
Good Clinical Practice and Regulatory Aspects Nora Espiritu MD, MPh, PhD (c) Former Executive Director of Research and Technology Transfer. Peruvian National Institute t of Health. Member of the Ethics
More informationManaging Research in Hospices
Managing Research in Hospices Paul Perkins Consultant in Palliative Medicine Gloucestershire Hospitals NHS Foundation Trust and Sue Ryder Leckhampton Court Hospice Cheltenham Why? We need to know what
More informationBurton Hospitals NHS Foundation Trust. Committee On: 19 May 2015. Review Date: March 2018. Corporate / Directorate
POLICY DOCUMENT Burton Hospitals NHS Foundation Trust RESEARCH GOVERNANCE AND INNOVATION POLICY Approved by: Executive Management Committee On: 19 May 2015 Review Date: March 2018 Corporate / Directorate
More informationStudy-wide considerations: identifies the areas of the criterion the lead reviewer should consider when conducting the review
UK STUDY-WIDE GOVERNANCE CRITERIA FOR R&D REVIEW INTRODUCTION The following document is intended to provide operational guidance to the person taking the UK lead in conducting the R&D Study-Wide review
More informationLaurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
More informationJob Profile Clinical Research Associate III (CRA)
PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed
More informationMRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council
MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR
More informationThe Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis
The Monitoring Visit Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis Disclosure The information herein is not intended to
More informationPROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group
European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197228/2005 Procedure no.: INS/GCP/2 PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA GCP Inspectors Working Group
More informationRole of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.
Role of IRB/IEC in GCP Benjamin Kuo, MD, Dr.PH, CIP. Institutional Review Board (IRB) An independent body constituted of medical, scientific and non scientific members Responsible for ensuring protection
More informationDate : Date of start of procedure: Authorisation/ positive opinion :
Substantial Amendment Notification Form (Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use,
More informationRD SOP17 Research data management and security
RD SOP17 Research data management and security Version Number: V2 Name of originator/author: Dr Andy Mee, R&I Manager Name of responsible committee: R&I Committee Name of executive lead: Medical Director
More informationClinical research: where are we with the new (Paediatric) RC trial Regulation
where are we with the new (Paediatric) RC trial Regulation, MD, PhD Ethical Committee DEEP Former member of the PDCO EMA With the aid of Fabio D'Atri European commission and Anabela Marcal of EMA The new
More informationNo. 706. Page 1 of 5. Issue Date 4/21/2014
Subject: ROUTINE MONITORING VISITS Standard Operating Procedure Prepared By: Beaumont Research Coordinating Center, Research Institute PURPOSE Prior Issue Date 8/15/2011 No. 706 Issue Date 4/21/2014 Page
More informationDocument Number: SOP/RAD/SEHSCT/007 Page 1 of 17 Version 2.0
Standard Operating Procedures (SOPs) Research and Development Office Title of SOP: Computerised Systems for Clinical Trials SOP Number: 7 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013
More informationGuide to Regulatory Requirements for the Procurement of Human Tissues and Cells intended for Human Application
Guide to Regulatory Requirements for the Procurement of Human Tissues and Cells intended for Human AUT-G0102-1 3 JANUARY 2013 This guide does not purport to be an interpretation of law and/or regulations
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationThe new EU Clinical Trials Regulation How NHS research and patients will benefit
the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of
More informationBiotech Concerto #3. European Clinical Trial Environment
Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart
More informationUK policy framework for health and social care research. Issued for public consultation
UK policy framework for health and social care research Issued for public consultation Introduction and background 1. Context... 1 2. Purpose... 2 3. Scope... 3 4. Implementation... 4 5. UK-wide responsibilities...
More informationDepartment of Health - Research Governance Framework (RGF)
LIVERPOOL JOHN MOORES UNIVERSITY SPONSORSHIP OF RESEARCH PROJECTS UNDER THE RESEARCH GOVERNANCE FRAMEWORK FOR HEALTH AND SOCIAL CARE April 2015 1 Background The Department of Health s Research Governance
More information23. The quality management system
23. The quality management system Version 2.0 On this page: Mandatory requirements: Extracts from the HFE Act Extracts from licence conditions HFEA guidance: Definition of the quality management system
More informationGuidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes
Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Norway
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Norway Question 1: What laws or regulations apply to an application for conducting a clinical
More information20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements
More informationHealth Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
More information